推荐产品
等级
certified reference material
形式
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol with 0.1N NaOH
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
pharmaceutical (small molecule)
格式
single component solution
储存温度
−20°C
SMILES字符串
O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)
InChI key
FBOZXECLQNJBKD-UHFFFAOYSA-N
一般描述
经认证的加标溶®液，用于通过HPLC或LC/MS进行治疗药物监测（TDM）分析。甲氨蝶呤用于癌症和自身免疫性疾病的治疗，是一种抗代谢和抗叶酸药物，由临床实验室监测，以确保患者保持在药物治疗范围内。Snap-N-Spike®格式允许实验室消除甲氨蝶呤等有害物质的称重操作，显著减少与处理急性毒性粉末有关的职业暴露危害，并提供在使用前将其加标到其选择的基质中的能力。
应用
- Pharmacokinetic analysis: Methotrexate solution is employed in advanced pharmacokinetic studies using UV-Vis spectrophotometric and colorimetric methods. This application facilitates precise quantification in plasma and tissue, crucial for evaluating drug distribution and effectiveness in cancer treatments (Febrianti et al., 2024).
- Toxicity and safety monitoring: Observational studies utilize Methotrexate solution to investigate root causes of medication errors and manage toxicity in elderly patients. This research supports safer clinical practices by identifying risk factors and improving patient safety protocols (Bisht et al., 2024).
- Nephrotoxicity prevention: Research on Methotrexate solution examines hydration strategies to mitigate nephrotoxicity, enhancing therapeutic outcomes. This study is pivotal in optimizing Methotrexate use in clinical settings, ensuring higher safety and efficacy for patients undergoing chemotherapy (Hasanpour et al., 2024).
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1
靶器官
Eyes,Central nervous system
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
51.8 °F - closed cup
闪点(°C)
11 °C - closed cup
法规信息
危险化学品
Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
J Westra et al.
Clinical and experimental immunology, 178(1), 40-47 (2014-06-04)
Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM
Josef S Smolen et al.
Lancet (London, England), 383(9914), 321-332 (2013-10-31)
Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
James R O'Dell et al.
The New England journal of medicine, 369(4), 307-318 (2013-06-13)
Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. We
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门